Gilead disputes report that coronavirus drug trial flopped

(Reuters) - Gilead Sciences Inc's experimental coronavirus drug failed its first randomized clinical trial, the Financial Times reported on Thursday, but the drugmaker said the results from the study in China was inconclusive as it was terminated early. Shares of Gilead fell nearly 6% to $76.56 after the FT story, which comes days after a recent report detailed rapid recovery in fever and respiratory symptoms in COVID-19 patients at the University of Chicago Medicine hospital.The Chinese..